Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Cinryze is a prescription human C1 esterase inhibitor used for routine prevention of hereditary angioedema attacks. It is approved for adults, adolescents, and children age 6 and older. Cinryze is given by intravenous infusion after the freeze-dried powder is mixed with sterile water.
read more about cinryze ...C1 inhibitor is a normal blood protein that regulates complement, contact-system, and fibrinolytic pathways. People with hereditary angioedema have low levels or reduced function of this protein. Cinryze raises functional C1 inhibitor activity and suppresses contact-system activation, which reduces bradykinin generation and vascular permeability linked to swelling attacks.
Cinryze is approved for routine prophylaxis against hereditary angioedema attacks in adults, adolescents, and children age 6 and older. It is used to reduce attack frequency rather than to treat an acute attack after symptoms have started. Pediatric dosing differs from dosing for patients age 12 and older.
Adults and adolescents age 12 and older receive 1000 IU intravenously every three or four days. Children age 6 to 11 receive 500 IU every three or four days. Dose increases are permitted for inadequate response within current labeling limits. Infusion time is about 10 minutes for 1000 IU and 5 minutes for 500 IU.
Serious hypersensitivity reactions, including anaphylaxis, can occur during or after infusion. Arterial and venous thromboembolic events have also been reported, especially in patients with underlying risk factors. Since Cinryze is made from human plasma, a residual risk of transmitting infectious agents remains despite donor screening and viral reduction steps.
Cinryze is used for routine prevention of hereditary angioedema attacks.
Routine dosing is every three or four days, with the dose based on age and clinical response.
Yes. Current labeling includes children age 6 and older.
No. Cinryze is labeled for routine prophylaxis rather than treatment of an acute hereditary angioedema attack.
C1-Esterase Inhibitor Human Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a622016.html. Date Accessed September 22, 2026.
CINRYZE. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/cinryze. Date Accessed September 22, 2026.
CINRYZE (C1 esterase inhibitor [human]) Prescribing Information. https://www.fda.gov/media/75907/download. Date Accessed September 22, 2026.
CINRYZE (C1 esterase inhibitor [human]) Treatment Information. https://www.cinryze.com/. Date Accessed September 22, 2026.
DailyMed - CINRYZE (human C1-esterase inhibitor) injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d53a911f-070d-498a-8a61-baab72b9d0fe. Date Accessed September 22, 2026.